Research
Hormonal
Dual and poly-agonists (e.g., Tirzepatide) targeting multiple receptors (GLP-1R, GIPR) provide superior weight loss compared to single-agonist GLP-1 therapies.
Dual-agonist drugs like Tirzepatide target both GLP-1 and GIP receptors, offering greater weight loss (up to 21%) than single-agonist GLP-1 drugs. This approach leverages multiple hormonal pathways for enhanced efficacy. It is a once-weekly injection suitable for those who need more potent weight loss support.
StrongSupportsVERY_HIGH confidence
Combining multiple biological mechanisms into a single molecule has resulted in multi-receptor agonists that are more effective than the individual mono-agonists.
Why this rating
Supported by Phase 3 trial data for Tirzepatide showing higher weight loss than Semaglutide.
Source
Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides
Søren Østergaard · Expert Opinion on Drug Discovery · 2025
narrative_reviewCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →